
Opinion|Podcasts|March 13, 2024
Widening the Therapeutic Window in the Management of Parkinson’s Disease
Listen
0:00 / 0:00
Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.
Advertisement
1:12 Long-term challenges
4:00 Levodopa fluctuations
6:30 Therapeutic window
9:20 Amantadine DR/ER for PD
11:30 Dyskinesia treatment
18:10 Amantadine candidates
23:34 PK of amantadine
27:15 Early treatment
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Poster Shows Etalanetug Reduced Tau Pathology Biomarkers in Dominantly Inherited Alzheimer Disease
2
Alzheimer Trial PRImus-AD Tests Orally Available PRI-002 as New Treatment
3
Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug
4
New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease
5


































